Role of advanced glycation end products in diabetic neuropathy

Current Pharmaceutical Design

Volumn 14, Issue 10, 2008, Pages 953-961

  Sugimoto, Kazuhiro ^a   Yasujima, Minoru ^a   Yagihashi, Soroku ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

AGEs; CML; Diabetic neuropathy; Oxidative stress; RAGE

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 2,3 DIAMINOPHENAZONE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ALAGEBRIUM; AMINOGUANIDINE; BENFOTIAMINE; CYTOKINE; FREE RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELIN PROTEIN; N PHENACYL 4,5 DIMETHYLTHIAZOLIUM; N PHENACYLTHIAZOLIUM BROMIDE; PENTOSIDINE; PLACEBO; POLYOL; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE; TENILSETAM; THIAZOLIDINE DERIVATIVE;

CLINICAL TRIAL; DEMYELINATION; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIVER FUNCTION TEST; LONG TERM CARE; LOW DRUG DOSE; MICROANGIOPATHY; NERVE FIBER DEGENERATION; NERVE FIBER TRANSPORT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; UPREGULATION; VASCULITIS;

ANIMALS; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MYELIN SHEATH; OXIDATIVE STRESS; PERIPHERAL NERVES; RATS; RECEPTORS, IMMUNOLOGIC; SKIN;

EID: 44449172015     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784139774     Document Type: Review

References (122)

1. Vinik A, Ullal J, Parson HK, Casellini CM. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab 2006; 2: 269-81.
2. Sugimoto K, Murakawa Y, Sima AAF. Diabetic neuropathy--a continuing enigma. Diabetes Metab Res Rev 2000; 16: 408-33.
3. Thornalley PJ. Glycation in diabetic neuropathy: Characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 2002; 50: 37-57.
4. Obrosova IG, Pacher P, Szabo C, Zsengeller Z, Hirooka H, Stevens MJ, et al. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 2005; 54: 234-42
5. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25: 612-28.
6. Nakamura J, Kato Y, Hamada Y, Nakayama M, Chaya S, Nakashima E, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48: 2090-5.
7. Yagihashi S, Yamagishi S, Wada R. Pathology and pathogenetic mechanisms of diabetic neuropathy: Correlation with clinical signs and symptoms. Diabetes Res Clin Pract 2007; 77(Suppl 1): S184-9.
8. Bierhaus A, Haslbeck KM, Humpert PM, Liliensiek B, Dehmer T, Morcos M, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004; 114: 1741-51.
9. Haslbeck KM, Neundorfer B, Schlotzer-Schrehardtt U, Bierhaus A, Schleicher E, Pauli E, et al. Activation of the RAGE pathway: A general mechanism in the pathogenesis of polyneuropathies? Neurol Res 2007; 29: 103-10.
10. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-808.
11. Meerwaldt R, Links TP, Graaff R, Hoogenberg K, Lefrandt JD, Baynes JW, et al. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005; 48: 1637-44.
12. Petersen A, Kappler F, Szwergold BS, Brown TR. Fructose metabolism in the human erythrocyte. Phosphorylation to fructose 3-phosphate. Biochem J 1992; 284(Pt 2): 363-6.
13. Baia R, James HM, Rofe AM, Conyers RA. The purification and properties of human liver ketohexokinase. A role for ketohexokinase and fructose-bisphosphate aldolase in the metabolic production of oxalate from xylitol. Biochem J 1985; 230: 53-60.
14. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Spl glycosylation. Proc Natl Acad Sci USA 2000; 97: 12222-6.
15. Takagi Y, Kashiwagi A, Tanaka Y, Asahina T, Kikkawa R, Shigeta Y. Significance of fructose-induced protein oxidation and formation of advanced glycation end product. J Diabetes Complicat 1995; 9: 87-91.
16. Lal S, Szwergold BS, Taylor AH, Randall WC, Kappler F, Wells-Knecht K, et al. Metabolism of fructose-3-phosphate in the diabetic rat lens. Arch Biochern Biophys 1995; 318: 191-9.
17. Niwa T. 3-Deoxyglucosone: Metabolism, analysis, biological activity, and clinical implication. J Chromatogr B Biomed Sci Appl 1999; 731: 23-36
18. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344(Pt 1): 109-16.
19. Thornalley PJ. Pharmacology of methylglyoxal: Formation, modification of proteins and nucleic acids, and enzymatic detoxification - a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 1996; 27: 565-73.
20. Thornalley PJ, Westwood M, Lo TW, McLellan AC. Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. Contrib Nephrol 1995; 112: 24-31.
21. Fukunaga M, Miyata S, Liu BF, Miyazaki H, Hirota Y, Higo S, et al. Methylglyoxal induces apoptosis through activation of p38 MAPK in rat Schwann cells. Biochem Biophys Res Commun 2004; 320: 689-95.
22. Takeuchi M, Yamagishi S. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. Med Hypotheses 2004; 63: 453-5.
23. Sekido H, Suzuki T, Jomori T, Takeuchi M, Yabe-Nishimura C, Yagihashi S. Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. Biochem Biophys Res Commun 2004; 320: 241-8.
24. Suzuki T, Sekido H, Kato N, Nakayama Y, Yabe-Nishimura C. Neurotrophin-3-induced production of nerve growth factor is suppressed in Schwann cells exposed to high glucose: Involvement of the polyol pathway. J Neurochem 2004; 91: 1430-8.
25. Yamagishi S, Uehara K, Otsuki S, Yagihasi S. Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice. J Neurochem 2003; 87: 497-507.
26. Uehara K, Yamagishi S, Otsuki S, Chin S, Yagihashi S. Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes 2004; 53: 3239-47.
27. Sorkin LS, Mao WH, Wagner R, Myers RR. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 1997; 81: 255-62.
28. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995; 38: 387-94.
29. Hamada Y, Araki N, Horiuchi S, Hotta N. Role of polyol pathway in nonenzymatic glycation. Nephrol Dial Transplant 1996; 11 Suppl 5: 95-8.
30. Phillips SA, Mirrlees D, Thornalley PJ. Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. Biochem Pharmacol 1993; 46: 805-11.
31. Yabe-Nishimura C, Nishinaka. T, Iwata. K, Seo HG. Up-regulation of aldose reductase by the substrate, methylglyoxal. Chem Biol Interact 2003; 143-144: 317-23.
32. Dan Q, Wong R, Chung SIC, Chung SS, Lam KS. Interaction between the polyol pathway and non-enzymatic glycation on aortic smooth muscle cell migration and monocyte adhesion. Life Sci 2004; 76: 445-59.
33. Dan Q, Wong RL, Yin S, Chung SK, Chung SS, Lam KS. Interaction between the polyol pathway and non-enzymatic glycation on mesangial cell gene expression. Nephron Exp Nephrol 2004; 98: E89-e99.
34. Lander HM, Tawas JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant strew. J Biol Chem 1997; 272: 17810-4.
35. Nishinaka T, Yabe-Nishimura C. EGF receptor-ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress. Free Radic Biol Med 2001; 31: 205-16.
36. Sugimoto K, Nishizawa Y, Horiuchi S, Yagihashi S. Localization in human diabetic peripheral nerve of N(epsilon)- carboxymethyl-lysine-protein adducts, an advanced glycation endproduct. Diabetologia 1997; 40: 1380-7.
37. Haslbeck KM, Schleicher ED, Friess U, Kirchner A, Neundorfer B, Heuss D. N(epsilon)-Carboxymethyllysine in diabetic and non-diabetic polyneuropathies. Acta Neuropathol 2002; 104:45-52.
38. Ryle C, Donaghy M. Non-enzymatic glycation of peripheral nerve proteins in human diabetics. J Neurol Sci 1995; 129: 62-8.
39. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
40. Arai K, Maguchi S, Fujii S, Ishibashi H, Oikawa K, Taniguchi N. Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites. J Biol Chem 1987; 262: 16969-72.
41. Yoshida K, Hirokawa J, Tagami S, Kawakami Y, Urata Y, Kondo T. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: Regulation of glutathione synthesis and efflux. Diabetologia 1995; 38: 201-10.
42. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801-13.
43. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
44. Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA 2006; 103: 2653-8.
45. Vincent AM, Olzmann JA, Brownlee M, Sivitz WI, Russell JW. Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death. Diabetes 2004; 53: 726-34.
46. Desco MC, Asensi M, Marquez R, Martinez-Valls J, Vento M, Pallardo FV, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: Protection by allopurinol. Diabetes 2002; 51: 1118-24.
47. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: Role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003; 14: S227-32.
48. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990; 173: 932-9.
49. Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997; 46: 1481-90.
50. Russell JW, Golovoy D, Vincent AM, Mahendru P, Olzmann JA, Mentzer A, et al. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 2002; 16: 1738-48.
51. Cotter MA, Cameron NE. Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci 2003; 73: 1813-24.
52. Schmeichel AM, Schmelzer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003; 52: 165-71.
53. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001; 50: 1927-37.
54. Cheng C, Zochodne DW. Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 2003; 52: 2363-71.
55. Ziegler D, Sohr CG, Nourooz-Zadeh J. Oxidative stress and anti-oxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004; 27: 2178-83
56. Hoeldtke RD, Bryner KD, McNeill DR, Hobbs GR, Riggs JE, Warehime SS, et al. Nitrosative stress, uric Acid, and peripheral nerve function in early type 1 diabetes. Diabetes 2002; 51: 2817-25.
57. Deuther-Conrad W, Loske C, Schinzel R, Dringen R, Riederer P, Munch G. Advanced glycation endproducts change glutathione redox status in SH-SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism. Neurosci Lett 2001; 312: 29-32.
58. Loske C, Neumann A, Cunningham AM, Nichol K, Schinzel R, Riederer P, et al. Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J Neural Transm 1998; 105: 1005-15.
59. Cellek S, Qu W, Schmidt AM, Moncada S. Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: A new insight into selective nitrergic neuropathy in diabetes. Diabetologia 2004; 47: 331-9.
60. Weimbs T, Stoffel W. Topology of CNS myelin proteolipid protein: evidence for the nonenzymatic glycosylation of extracytoplasmic domains in normal and diabetic animals. Biochemistry 1994; 33: 10408-15.
61. Vlassara H, Brownlee M, Cerami A. Excessive nonenzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats. Diabetes 1983; 32: 670-4.
62. Vlassara H, Brownlee M, Cerami A. Recognition and uptake of human diabetic peripheral nerve myelin by macrophages. Diabetes 1985; 34: 553-7.
63. Ryle C, Leow CK, Donaghy M. Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus. Muscle Nerve 1997; 20: 577-84.
64. Cullum NA, Mahon J, Stringer K, McLean WG. Glycation of rat sciatic nerve tubulin in experimental diabetes mellitus. Diabetologia 1991; 34: 387-9.
65. Williams SK, Howarth NL, Devenny JJ, Bitensky MW. Structural and functional consequences of increased tubulin glycosylation in diabetes mellitus. Proc Natl Acad Sci USA 1982; 79: 6546-50.
66. Pekiner C, Cullum NA, Hughes JN, Hargreaves AJ, Mahon J, Casson IF, et al. Glycation of brain actin in experimental diabetes. J Neurochem 1993; 61: 436-42.
67. Federoff HJ, Lawrence D, Brownlee M. Nonenzymatic glycosylation of laminin and the laminin peptide CIKVAVS inhibits neurite outgrowth. Diabetes 1993; 42: 509-13.
68. Luo ZJ, King RH, Lewin J, Thomas PK. Effects of nonenzymatic glycosylation of extracellular matrix components on cell survival and sensory neurite extension in cell culture. J Neurol 2002; 249: 424-31
69. Ozturk G, Sekeroglu MR, Erdogan E, Ozturk M. The effect of non-enzymatic glycation of extracellular matrix proteins on axonal regeneration in vitro. Acta Neuropathol 2006; 112: 627-32.
70. Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002; 1: 1-15.
71. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143: 1699-712.
72. Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam BG, Murray-McIntosh RP, et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 1997; 40: 619-28.
73. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-97.
74. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-43.
75. Vincent AM, Perrone L, Sullivan KA, Backus C, Sastry AM, Lastoskie C, et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 2007; 148: 548-58.
76. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000; 275: 40096-105.
77. Huttunen HJ, Kuja-Panula J, Rauvala H. Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J Biol Chem 2002; 277: 38635-46.
78. Haslbeck KM, Schleicher E, Bierhaus A, Nawroth P, Hasibeck M, Neundorfer B, et al. The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 2005; 113: 288-91.
79. Toth C, Rong LL, Yang C, Martinez J, Song F, Ramji N, et al. RAGE and experimental diabetic neuropathy. Diabetes 2007; Nov 26 [Epub ahead of print].
80. Srivastava AK. High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: A potential role in the pathogenesis of vascular dysfunction in diabetes (review). Int J Mol Med 2002; 9: 85-9.
81. Cameron NE, Cotter MA, Jack AM, Basso MD, Hohman TC. Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999; 42: 1120-30.
82. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-403.
83. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: A mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816-22.
84. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001; 17: 436-43.
85. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
86. Amano S, Kaji Y, Oshika T, Oka T, Machinami R, Nagai R, et al. Advanced glycation end products in human optic nerve head. Br J Ophthalmol 2001; 85: 52-5.
87. Del Carro U, Fiorina P, Amadio S, De Toni Franceschini L, Petrelli A, Menini S, et al. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: Neurophysiological and skin biopsy longitudinal analysis. Diabetes Care 2007; 30: 3063-9.
88. Misur I, Zarkovic K, Barada A, Batelja L, Milicevic Z, Turk Z. Advanced glycation endproducts in peripheral nerve in type 2 diabetes with neuropathy. Acta Diabetol 2004; 41: 158-66.
89. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 1992; 41: 1286-92.
90. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91: 2470-8
91. Beisswenger PJ, Moore LL, Brinck-Johnsen T, Curphey TJ. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 1993; 92: 212-7
92. Garay-Sevilla ME, Regalado JC, Malacara JM, Nava LE, Wrobel-Zasada K, Castro-Rivas A, et al. Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus. J Endocrinol Invest 2005; 28: 223-30.
93. Hwang JS, Shin CH, Yang SW. Clinical implications of N epsilon-(carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes. Diabetes Obes Metab 2005; 7: 263-7.
94. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004; 47: 1324-30.
95. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006; 29: 2654-9.
96. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992; 41: 47-52.
97. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 1991; 88: 6107-11.
98. Wada R, Sugo M, Nakano M, Yagihashi S. Only limited effects of aminoguanidine treatment on peripheral nerve function, (Na+,K+)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats. Diabetologia 1999; 42: 743-7.
99. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Yorek MA. Effect of treating streptozotocin-induced diabetic rats with sorbinil, myoinositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Int J Exp Diabetes Res 2002; 3: 21-36.
100. Coppey LJ, Gellett JS, Davidson EP, Yorek MA. Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res 2003; 37: 33-40.
101. Sugimoto & Yagihashi S. Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats. Microvasc Res 1997; 53: 105-12.
102. Birrell AM, Heffernan SJ, Ansselin AD, McLennan S, Church DK, Gillin AG, et al. Functional and structural abnormalities in the nerves of type I diabetic baboons: Aminoguanidine treatment does not improve nerve function. Diabetologia 2000; 43: 110-6.
103. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999; 20: 493-510.
104. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997; 46: 895-9.
105. Wada R, Nishizawa Y, Yagihashi N, Takeuchi M, Ishikawa Y, Yasumura K, et al. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001; 31: 513-20.
106. Vasan S, Zhang Y, Kapumiotu A, Bernhagen J, Teichberg S, Basgen J, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996; 382: 275-8.
107. Yang S, Litchfield JE, Baynes JW. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch Biochem Biophys 2003; 412: 42-6.
108. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104: 1464-70.
109. Demiot C, Tartas M, Fromy B, Abraham P, Saumet JL, Sigaudo-Roussel D. Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy. Diabetes 2006; 55: 1478-83.
110. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-9.
111. Pomero F, Molinar Min A, La Selva M, Allione A, Molinatti GM, Porta M. Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetol 2001; 38: 135-8.
112. Stracke H, Hammes HP, Werkmann D, Mavrakis K, Bitsch I, Netzel M, et al. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes 2001; 109: 330-6.
113. Sanchez-Ramirez GM, Caram-Salas NL, Rocha-Gonzalez HI, Vidal-Cantu GC, Medina-Santillan R, Reyes-Garcia G, et al. Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur J Pharmacol 2006; 530: 48-53.
114. Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 1996; 104: 311-6.
115. Haupt E, Ledermann H, Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy - a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005; 43: 71-7.
116. Cameron NE, Gibson TM, Naugle MR, Cotter MA. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann N Y Acad Sci 2005; 1043: 784-92.
117. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 1999; 13: 23-30.
118. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005; 54: 1615-25.
119. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-20.
120. Marshall SM. The podocyte: A potential therapeutic target in diabetic nephropathy? Curr Pharm Des 2007; 13(26): 2713-20.
121. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Curr Pharm Des 2007; 13(13): 1317-25.
122. Victor VM, Rocha M. Targeting antioxidants to mitochondria: A potential new therapeutic strategy for cardiovascular diseases. Curr Pharm Des 2007; 13(8): 845-63.